← Companies|Immunomedics (Gilead)
Im

Immunomedics (Gilead)

Morris Plains NJFounded 19831,200 employees
Private CapbiotechAcquiredOncology
Platform: Trodelvy ADC
Market Cap
N/A
All Drugs
4
Clinical Trials
9
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
SuraosocimabIMM-5097Phase 1/22NanobodyFLT3Cl18.2DravetCeliac
VoxavorutinibIMM-9672Phase 31NanobodyCD123MDM2iMCL
IMM-2816IMM-2816Approved4ADCCl18.2PD-1iLGSADPKD
IMM-5415IMM-5415Preclinical2ERTPD-1BCMA ADCParkinson'sWet AMD
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (9)
2025-06-14
Suraosocimab Ph2 Data
Celiac
Past
2025-08-14
Voxavorutinib Ph3 Readout
MCL
Past
2026-05-07
Suraosocimab Ph2 Data
Dravet
Ph2 Data
2028-05-20
IMM-2816 Ph3 Readout
LGS
Ph3 Readout
2029-03-04
IMM-5415 Interim
Parkinson's
Interim
2029-09-14
IMM-2816 Ph3 Readout
T2D
Ph3 Readout
2030-09-14
IMM-2816 Ph3 Readout
ADPKD
Ph3 Readout
2031-09-06
IMM-2816 Ph3 Readout
LGS
Ph3 Readout
2031-11-15
IMM-5415 Interim
Parkinson's
Interim